Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
about
Synthetic self-adjuvanting glycopeptide cancer vaccinesStrategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen ModificationAntibody recognition of fluorinated MUC1 glycopeptide antigens.Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy.Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouseLinear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune ResponsesFully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR StimulationNatural and Induced Humoral Responses to MUC1.Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.Carbohydrate chemistry in drug discovery.Designing a new antifungal glycoconjugate vaccine.Multivalent glyco(cyclo)peptides.Convergent chemo-enzymatic synthesis of mannosylated glycopeptides; targeting of putative vaccine candidates to antigen presenting cells.CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines.NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.Antibody induction directed against the tumor-associated MUC4 glycoprotein.Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines.Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response.Oxidative Deselenization of Selenocysteine: Applications for Programmed Ligation at Serine.Synthetic glycopeptides and glycoproteins with applications in biological research.Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.Vaccine Delivery Methods into the FutureRecent progress in antitumoral synthetic vaccines.The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope.Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS.C-Glycosyl amino acids through hydroboration-cross-coupling of exo-glycals and their application in automated solid-phase synthesis.Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.Solid phase oxime ligations for the iterative synthesis of polypeptide conjugates.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation.
P2860
Q26777837-7F90411B-15A7-45BD-9632-3241400A58C0Q27001592-175E5252-8434-4852-A297-4240EFC3CA57Q34045866-FD3DBD70-84FA-4AA6-9A4B-4FF884ABDE57Q34901076-99847FB6-DEDE-475D-BD10-8A86FD39BB0DQ35030845-CC136C6B-24DD-4F5E-BEC7-558E983BC24CQ35685656-551EEA5A-9464-446E-965C-292D575D8CC2Q35800918-D779919C-E0A5-4000-9772-6FF083DB74BFQ35854131-BB804834-DC87-4663-B102-ECEAB40DCD50Q36221411-6B0F4291-25ED-450E-9ACD-787FE021CEB5Q36501284-3DF9AD9A-3A57-4ECE-8D5C-1700154F77F2Q36604334-8F1AA111-E348-4914-8035-88D605006C5EQ36815144-912B3069-27C5-4813-A32B-9F7A4ACBAC00Q36850638-C9E776C9-6405-4ADE-AF1F-18E0A5C22E33Q36921721-83087F8F-0F5C-49DD-9212-D483C9AD3057Q37137385-74B437F5-7188-40CC-BFE7-6918C9020533Q37418500-263416AC-A4DF-4DDE-AD07-FD27A91A4958Q37853437-F2918CF7-9677-4FD8-BC25-789D714AE3A9Q38066728-C41ACF91-1CB2-473E-9887-EA2C80A164C7Q38069441-8F6CA2AF-3577-4C10-BF72-2B208DFF8224Q38297352-3A2A78D1-4DEE-44B3-A6AF-1D8865C22BB4Q38303467-FB66AB57-F1EF-4906-A322-1FAC412F5142Q38412832-7211E788-70B9-44D1-870F-7B6D38390E69Q38901814-1C95E0BD-0882-4C40-9115-413249E27A7EQ38962995-18560220-F3E9-4456-BA42-15D8AACC0C9AQ39254744-7F919578-2A08-415C-BA0C-CCF544AE987EQ39411787-42BE0705-45D4-439A-8119-CB9E974B32C1Q40524884-5F6FDB20-8614-421E-BDEE-3F7336834BE8Q41983543-F39EE876-2017-4C83-A6BA-EF06F7FB2DC2Q42021841-A578D95F-4340-4ECE-BC52-E8A3DCED5003Q42434139-BC31FB16-DB87-48EE-BBD0-1F062DB61A18Q43007810-45CFCDC2-D853-4223-9FA0-36DC5F6818FDQ43540864-2A44B765-589D-4231-9262-C0ABC14D9CEDQ44527454-8B0B5D79-FEF2-45E4-9E6C-48A542254ED5Q45157481-8E527469-AE6D-464B-ACAA-4D185B84A38EQ45183757-70DD9E64-7DEC-48F3-9C18-BCB2493DB155Q45350056-ABDA6832-FC56-4A16-AD4D-B35608D037A8Q47590580-7AF31D20-E2A5-4300-8C3A-CF08B746188AQ47626278-4E8E9A77-D936-438A-81D9-38449D8D3B20Q48169265-59FE66A1-A07E-4371-A0DD-E7B2E5DDDDDAQ48761437-42CE9F30-051B-49AD-84D3-7B5B9A995F2E
P2860
Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@en
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@nl
type
label
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@en
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@nl
prefLabel
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@en
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer.
@nl
P2860
P50
P356
P1476
Self-adjuvanting multicomponen ...... receptor 2 agonist Pam3CysSer
@en
P2093
Richard J Payne
Stephanie Day
P2860
P304
P356
10.1002/ANIE.201006115
P407
P577
2011-01-07T00:00:00Z